Suchergebnisse - "Rendell, Marc S."

PubPharm (56)

11

Albiglutide for the management of type 2 diabetes

enthalten in: Expert review of endocrinology & metabolism | 2018

von Rendell, M.

12

Efficacy and safety of MK‐1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes : A randomized, open‐label clinical trial

enthalten in: Diabetes, Obesity and Metabolism | 2018

von Hollander, P. | Carofano, W. | Lam, R. | +8

13

The safety of albiglutide for the treatment of type 2 diabetes

enthalten in: Expert opinion on drug safety | 2017

von Rendell, M.

14

The safety of albiglutide for the treatment of type 2 diabetes

enthalten in: Expert opinion on drug safety | 2017

von Rendell, M.

15

Albiglutide : a unique GLP-1 receptor agonist

enthalten in: Expert opinion on biological therapy | 2016

von Rendell, M.

16

Albiglutide: a unique GLP-1 receptor agonist

enthalten in: Expert opinion on biological therapy | 2016

von Rendell, M.

17

Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment : a randomised clinical trial

enthalten in: Diabetologia | 2015

von Kothny, W. | Lukashevich, V. | Foley, J. | +2

18

Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients

enthalten in: The Journal of clinical investigation | 2015

von Rigby, M. | Harris, K. | Pinckney, A. | +24

19

Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial

enthalten in: Diabetologia | 2015

von Kothny, W. | Lukashevich, V. | Foley, J. | +2

20

Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial

enthalten in: Diabetologia | 2015

von Kothny, W. | Lukashevich, V. | Foley, J. | +2